Navigation Links
InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
Date:11/8/2007

Molecular Endocrinology at the University of Chicago with Drs. Kenneth Polonski and Graham Bell. His clinical and research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen to build the Metabolic Disease Area and direct the Leptin program. At Amgen he also directed the development of a broad array of metabolic disease targets focused on translating novel pathways into the clinic. These pathways include 11 Beta HSD-1, RANK Ligand, calcium sensing receptor, PPAR-gamma modulation, and MCH-R1. He also maintains his clinical practice.

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages under the direction of InteKrin's accomplished management team and world-class SAB. The company was co-founded by Chief Executive Denny Lanfear, a former Amgen VP and Officer, and by Scientific Advisory Board Chair Christos Mantzoros, M.D., D.Sc., a leading clinical endocrinologist and Associate Professor at Harvard Medical School. InteKrin's team of world-class scientific and medical experts includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders who brought earlier PPAR agonists to market.

InteKrin's lead therapeutic candidate, INT131, is a potent non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) that was specifically engineered to have equal or better efficacy to the cu
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. WorldHeart Appoints David Pellone Chief Financial Officer
9. Novo Nordisk Appoints New Leader of North American Business
10. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
11. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... East Brunswick, NJ (PRWEB) September 17, 2014 ... its Static Application Security Testing (SAST) tool, at AppSec ... the 19th from 9 am to 6 pm at ... 2014 is one of the leading software security conferences ... SPARROW is a tool that provides developers and managers ...
(Date:9/17/2014)... Journal of Surgery ( IJS ) has announced that ... after 24 months published journal issues become available for all ... is to improve surgical knowledge and patient care and it ... will improve efforts to achieve this. , Professor David ... always been a great place for authors to publish and ...
(Date:9/17/2014)... coupled to a progressive decline in signal transduction and ... at Karolinska Institutet in Sweden. The finding, which is ... new molecular mechanism underlying age-related impairment of insulin-producing cells ... risk factors for many diseases, and type 2 diabetes ... an increased risk of developing type 2 diabetes if ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... In a continuing effort to protect local athletes ... Shield of the South Shore has partnered for the ... Athletic Association to treat area fields in preparation for ... dusk, prime mosquito feeding time, the exposure to mosquito-borne ... involved in outdoor athletic activities. , Rob and Lisa ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2
... obstacles towards progress in the developing world is the ... been seriously addressed by the public health community. ... People, Forgotten Diseases, published by ASM Press. , Some ... too long been ignored. Parasitic and bacterial diseases ...
... Ohio, April 8, 2008 Cardinal Health,Inc. (NYSE: CAH ... safety and productivity of health care, plans to release third-quarter,results ... opening of trading,on the New York Stock Exchange., The ... 1 at,8:30 a.m. EDT to discuss results of the quarter. ...
... small trial, new study finds no effect , , TUESDAY, ... don,t help prevent relapses in patients with Crohn,s disease, ... of the Journal of the American Medical Association ... lead author Dr. Brian Feagan, professor of medicine and ...
... tea have long held a place in traditional medicine in ... health and long life and for the treatment of specific ... the bodys immune functions and hold the potential for treatment ... Now a new study by Chinese scientists found that combining ...
... 8, 2008 The numbers tell the,story, Vicki Hoak, ... the Senate Aging and Youth Committee today.,The Medicaid reimbursement ... is $67,000,per person. For an acute care hospital, the ... is just $21,000., Since the Governor and legislators ...
... Light San Diego Pink Day, SAN DIEGO, April ... world,s largest grassroots network of breast cancer survivors and,activists ... San Diego Affiliate will award $960,000 in grants to ... underinsured women and men in,San Diego receive breast cancer ...
Cached Medicine News:Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 2Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 4
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... CARLSBAD, Calif. , Sept. 17, 2014 /PRNewswire/ ... ) announced that it has earned a $4 ... AKAO ) associated with the initiation of ... with serious multi-drug resistant (MDR), gram-negative bacterial infections.  ... superiority study to evaluate the efficacy and safety ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: